Substance / Medication

Argatroban

Overview

Active Ingredient
argatroban
RxNorm CUI
15202
Labeler: Mullan Pharmaceutical Inc.Updated: 2025-09-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Argatroban is contraindicated in: Warnings and Precautions (5.1) [see] Patients with major bleeding, Adverse Reactions (6.1) [see] Patients with a history of hypersensitivity to argatroban. Airway, skin, and generalized hypersensitivity reactions have been reported

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

9 trials linked to this intervention

9
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Exploring the Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke Patients: A Systematic Review and Meta-analysis.
Ahmed Yousr, Moawad Mostafa Hossam El Din, Bahtiyarova Gulnaz et al. · Transl Stroke Res · 2025
PMID: 40392513Meta-AnalysisFull text (PMC)
Efficacy and safety of argatroban in the management of acute ischemic stroke: A systematic literature review and meta-analysis.
Al-Salihi Mohammed Maan, Saha Ram, Ayyad Ali et al. · Clin Neurol Neurosurg · 2024
PMID: 38176219Meta-Analysis
Efficacy and safety of Argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis.
Cheng YiRan, Liu ChangNing, Li ShanShan et al. · Front Neurol · 2024
PMID: 38440113Meta-AnalysisFull text (PMC)
Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review.
Geli Janos, Capoccia Massimo, Maybauer Dirk M et al. · J Intensive Care Med · 2022
PMID: 33653194Meta-Analysis
Effects of argatroban therapy for stroke patients: A meta-analysis.
Hou Xiaojun, Jin Chunfeng, Pan Chengli et al. · J Clin Neurosci · 2021
PMID: 34275554Meta-Analysis
[Meta-analysis of the role of Argatroban in renal replacement therapy].
Cao Fang-fang, Zhang Hai-tao, Feng Xue et al. · Zhongguo Yi Xue Ke Xue Yuan Xue Bao · 2013
PMID: 24382247Meta-Analysis
Argatroban anticoagulation in renal dysfunction: a literature analysis.
Hursting Marcie J, Murray Patrick T · Nephron Clin Pract · 2008
PMID: 18560242Meta-Analysis
Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.
Roy Akash, Elm Jordan, Ingles James R et al. · Neurology · 2025
PMID: 41071964RCT
Argatroban plus alteplase in posterior versus anterior circulation stroke.
Cui Yu, Chen Hui-Sheng · Ann Clin Transl Neurol · 2025
PMID: 39675018RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Argatroban (substance)
SNOMED CT
116508003
UMLS CUI
C0048470
RxNorm CUI
15202
Labeler
Mullan Pharmaceutical Inc.

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
9
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.